Navegando por Palavras-chave "antifungal therapy"

Agora exibindo 1 - 2 de 2
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    The multitude of targets for the immune system and drug therapy in the fungal cell wall
    (Elsevier B.V., 2005-04-01) Nimrichter, Leonardo [UNIFESP]; Rodrigues, M. L.; Rodrigues, Elaine G. [UNIFESP]; Travassos, Luiz R. [UNIFESP]; Universidade Federal do Rio de Janeiro (UFRJ); Universidade Federal de São Paulo (UNIFESP)
    Recent studies on fungi revealed that several cytosolic and membrane components migrate to the cell wall together with secreted proteins and biosynthetic polysaccharides to build a dynamic immunoreactive structure. New aspects of fungal cell wall assembly and biosynthesis, focusing on the potential of glycolipids, melanin, heat-shock proteins, historic and surface antigens as targets of drugs and antifungal anti-bodies are discussed. (c) 2005 Elsevier SAS. All rights reserved.
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Poly(lactic acid-glycolic acid) nanoparticles markedly improve immunological protection provided by peptide P10 against murine paracoccidioidomycosis
    (Wiley-Blackwell, 2010-03-01) Amaral, Andre C.; Marques, Alexandre F.; Munoz, Julian E.; Bocca, Anamelia L.; Simioni, Andreza R.; Tedesco, Antonio C.; Morais, Paulo C.; Travassos, Luiz Rodolpho [UNIFESP]; Taborda, Carlos Pelleschi [UNIFESP]; Felipe, Maria Sueli S.; Universidade de Brasília (UnB); Univ Catolica Brasilia; Universidade de São Paulo (USP); Universidade Federal de São Paulo (UNIFESP)
    Background and purpose:The present study reports on the preparation and testing of a sustained delivery system for the immunomodulatory peptide P10 aimed at reducing the in vivo degradation of the peptide and the amount required to elicit a protective immune response against paracoccidioidomycosis.Experimental approach:BALB/c mice were infected with the yeast Paracoccidioides brasiliensis to mimic the chronic form of paracoccidioidomycosis. the animals were treated daily with sulfamethoxazole/trimethoprim alone or combined with peptide P10, either emulsified in Freund's adjuvant or entrapped in poly(lactic acid-glycolic acid) (PLGA) nanoparticles at different concentrations (1 mu g, 5 mu g, 10 mu g, 20 mu g or 40 mu g center dot 50 mu L-1). Therapeutic efficacy was assessed as fungal burden in tissues and the immune response by quantitative determination of cytokines.Key results:Animals given combined chemotherapy and P10 nanotherapy presented a marked reduction of fungal load in the lungs, compared with the non-treated animals. After 30 days of treatment, P10 entrapped within PLGA (1 mu g center dot 50 mu L-1) was more effective than 'free' P10 emulsified in Freund's adjuvant (20 mu g center dot 50 mu L-1), as an adjuvant to chemotherapy. After treatment for 90 days, the higher doses of P10 entrapped within PLGA (5 or 10 mu g center dot 50 mu L-1) were most effective. Treatment with P10 emulsified in Freund's adjuvant (20 mu g center dot 50 mu L-1) or P10 entrapped within PLGA (1 mu g center dot 50 mu L-1) were accompanied by high levels of interferon-gamma in lung.Conclusions and implications:Combination of sulfamethoxazole/trimethoprim with the P10 peptide entrapped within PLGA demonstrated increased therapeutic efficacy against paracoccidioidomycosis. P10 incorporation into PLGA nanoparticles dramatically reduced the peptide amount necessary to elicit a protective effect.